Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
Fate Therapeutics will discuss FT819, its Phase 2 RECLAIM-LN trial and safety design at Cantor’s 2026 healthcare conference, with a webcast replay.
Rhea-AI Summary
Fate Therapeutics (FATE) will participate in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference on September 9, 2026, in New York, NY.
Management will discuss FT819, its off-the-shelf CAR T-cell candidate for autoimmune diseases, the Phase 2 RECLAIM-LN lupus nephritis trial, and FT819’s safety design, and will host one-on-one investor meetings. The session will be webcast with a 30-day replay on the company’s website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 14 | Clinical trial initiation | Positive | +2.0% | RECLAIM-LN began with first lupus nephritis patient dosed in an outpatient setting. |
| Aug 13 | 2Q26 earnings report | Negative | -7.3% | Quarterly loss and cash decline accompanied clinical and regulatory pipeline updates. |
| Aug 03 | Employee equity awards | Negative | +2.8% | Inducement awards covered options and RSUs for newly hired non-executive employees. |
| Jul 09 | FDA IND clearance | Positive | +6.1% | FDA cleared the FT839 investigational new drug application for autoimmune disease. |
| Jul 06 | Preliminary clinical data | Positive | +2.4% | Early FT819 systemic-sclerosis data reported clinical improvement without specified safety events. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
FATE's recent news reactions were mixed, with positive clinical and regulatory announcements generally aligning with gains while the earnings release diverged negatively.
Key Terms
induced pluripotent stem cell medical
car t-cell medical
lupus nephritis medical
phase 2 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference, being held September 9–12, 2026 in New York, NY. Discussion topics will include an overview of the differentiated and favorable tolerability and meaningful clinical activity seen with FT819, the Company’s off-the-shelf CAR T-cell product candidate for the treatment of various autoimmune diseases. The conversation will also focus on the commencement of RECLAIM-LN, the Phase 2 potentially registrational trial in lupus nephritis, as well as the unique safety elements that are incorporated into the design of FT819. Management will also host one-on-one meetings with investors during the conference.
2026 Annual Cantor Global Healthcare Conference
Date: Wednesday, September 9, 2026
Time: 9:45 a.m. EDT
Location: New York, NY
Webcast: Fate Fireside Chat
An archived replay of the webcast will be available for 30 days on the Company’s website following the event under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the Company's product candidates, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, the initiation and continuation of enrollment in the Company’s clinical trials, the clinical, therapeutic and market potential of the Company’s research and development programs and product candidates, and the Company’s clinical and product development strategy. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company’s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects, and risks relating to regulatory interactions and the outcome of such interactions. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Contact:
Ryan Douglas
Fate Therapeutics, Inc.
IR@fatetherapeutics.com
